NASDAQ:KROS

Keros Therapeutics (KROS) Stock Forecast, Price & News

$43.89

-5.07 (-10.36%)

(As of 06/9/2023 ET)

Compare

Today's Range: $42.23
▼
$47.62
50-Day Range: $37.26
▼
$51.01
52-Week Range: $24.38
▼
$59.96

Volume: 1.13 million shs
Average Volume: 174,921 shs
Market Capitalization: $1.30 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $103.75

Keros Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 136.4% Upside
$103.75 Price Target
Short Interest: Healthy
3.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.44) to ($5.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

189th out of 988 stocks

Pharmaceutical Preparations Industry

80th out of 479 stocks

3.5

Analyst's Opinion

Consensus Rating
Keros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $103.75, Keros Therapeutics has a forecasted upside of 136.4% from its current price of $43.89.
Amount of Analyst Coverage
Keros Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.34% of the float of Keros Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Keros Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Keros Therapeutics has recently increased by 12.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Keros Therapeutics does not currently pay a dividend.
Dividend Growth
Keros Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KROS.

3.3

News and Social Media Coverage

News Sentiment
Keros Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Keros Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.00% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.14% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Keros Therapeutics are expected to grow in the coming year, from ($5.44) to ($5.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Keros Therapeutics is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Keros Therapeutics is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Keros Therapeutics has a P/B Ratio of 4.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KROS Stock News Headlines

June 9, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)

June 9, 2023 | finance.yahoo.com

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

June 10, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

June 7, 2023 | finance.yahoo.com

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

May 29, 2023 | markets.businessinsider.com

Keros Therapeutics (KROS) Receives a Rating Update from a Top Analyst

May 23, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN) and Keros Therapeutics (KROS)

May 22, 2023 | finance.yahoo.com

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

May 11, 2023 | finance.yahoo.com

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 10, 2023 | americanbankingnews.com

HC Wainwright Comments on Keros Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:KROS)

May 9, 2023 | msn.com

HC Wainwright & Co. Reiterates Keros Therapeutics (KROS) Buy Recommendation

May 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Keros Therapeutics (KROS)

May 7, 2023 | seekingalpha.com

Keros Therapeutics GAAP EPS of -$1.26

May 7, 2023 | americanbankingnews.com

Piper Sandler Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $110.00

May 7, 2023 | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Buy" by Analysts

May 6, 2023 | nasdaq.com

Piper Sandler Maintains Keros Therapeutics (KROS) Overweight Recommendation

May 5, 2023 | finanznachrichten.de

Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

May 4, 2023 | msn.com

Recap: Keros Therapeutics Q1 Earnings

May 4, 2023 | finance.yahoo.com

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

May 1, 2023 | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

April 30, 2023 | seekingalpha.com

Keros Therapeutics: Undercovered Company With Data From All Programs

April 22, 2023 | americanbankingnews.com

Keros Therapeutics (NASDAQ:KROS) Trading 3.7% Higher

April 19, 2023 | finance.yahoo.com

Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

April 18, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Keros Therapeutics (KROS)

April 10, 2023 | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $106.25 Consensus Price Target from Analysts

April 2, 2023 | americanbankingnews.com

Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Rises By 19.3%

April 1, 2023 | americanbankingnews.com

Keros Therapeutics (NASDAQ:KROS) Shares Down 3.8%

See More Headlines

KROS Price History

30 days | 90 days | 365 days | Advanced Chart

KROS Company Calendar

Last Earnings: 5/04/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KROS
CUSIP: N/A
CIK: 1664710
Web: www.kerostx.com
Phone: 617-314-6297
Fax: N/A
Employees: 60
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $103.75
High Stock Price Forecast: $110.00
Low Stock Price Forecast: $100.00
Forecasted Upside/Downside: +136.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,680,000.00
Net Margins: N/A
Pretax Margin: -399.51%
Return on Equity: -42.89%
Return on Assets: -39.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.43
Quick Ratio: 23.43

Sales & Book Value

Annual Sales: $20.10 million
Price / Sales: 64.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.07 per share
Price / Book: 4.36

Miscellaneous

Outstanding Shares: 29,584,000
Free Float: 21,300,000
Market Cap: $1.30 billion
Optionable: Not Optionable
Beta: 1.22

Key Executives

Dr. Jasbir S. Seehra Ph.D. (Age 66)
Pres, CEO, Treasurer, & Director
Comp: $908.09k

Mr. Keith C. Regnante MBA (Age 52)
Chief Financial Officer
Comp: $603.24k

Dr. Jennifer Lachey Ph.D. (Age 49)
Chief Scientific Officer
Comp: $604.74k

Mr. Christopher Rovaldi M.Sc. (Age 48)
Chief Operating Officer

Ms. Esther Cho J.D.
Head of Legal & Corp. Sec.

Ms. Robin Wagner
VP of HR

Dr. Simon Cooper MBBS (Age 52)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KROS Stock - Frequently Asked Questions

Should I buy or sell Keros Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KROS shares.
View KROS analyst ratings or view top-rated stocks.
What is Keros Therapeutics' stock price forecast for 2023?: 5 brokers have issued 12-month price targets for Keros Therapeutics' stock. Their KROS share price forecasts range from $100.00 to $110.00. On average, they expect the company's share price to reach $103.75 in the next year. This suggests a possible upside of 136.4% from the stock's current price.
View analysts price targets for KROS or view top-rated stocks among Wall Street analysts.
How have KROS shares performed in 2023?: Keros Therapeutics' stock was trading at $48.02 on January 1st, 2023. Since then, KROS stock has decreased by 8.6% and is now trading at $43.89.
View the best growth stocks for 2023 here.
When is Keros Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our KROS earnings forecast.
How were Keros Therapeutics' earnings last quarter?: Keros Therapeutics, Inc. (NASDAQ:KROS) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by $0.12. During the same quarter in the prior year, the business posted ($1.01) earnings per share.
What ETFs hold Keros Therapeutics' stock?: ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), BlackRock Future Health ETF (BMED), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Keros Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).
When did Keros Therapeutics IPO?: (KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
What is Keros Therapeutics' stock symbol?: Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS."
Who are Keros Therapeutics' major shareholders?: Keros Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (13.70%), BlackRock Inc. (5.67%), Price T Rowe Associates Inc. MD (3.90%), State Street Corp (3.19%), Candriam S.C.A. (2.52%) and First Light Asset Management LLC (2.01%). Insiders that own company stock include Christopher Rovaldi, Claudia Ordonez, Jennifer Lachey, Julius Knowles, Ran Nussbaum and Richard K Prins.
View institutional ownership trends.
How do I buy shares of Keros Therapeutics?: Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Keros Therapeutics' stock price today?: One share of KROS stock can currently be purchased for approximately $43.89.
How much money does Keros Therapeutics make?: Keros Therapeutics (NASDAQ:KROS) has a market capitalization of $1.30 billion and generates $20.10 million in revenue each year. The company earns $-104,680,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis.
How can I contact Keros Therapeutics?: Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for the company is www.kerostx.com. The company can be reached via phone at 617-314-6297 or via email at jbalanova@troutgroup.com.

This page (NASDAQ:KROS) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial